---
document_datetime: 2025-11-23 07:04:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/orlaam.html
document_name: orlaam.html
version: success
processing_time: 0.0437338
conversion_datetime: 2025-12-26 17:10:10.266123
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Orlaam

[RSS](/en/individual-human-medicine.xml/65825)

##### Withdrawn

This medicine's authorisation has been withdrawn

levacetylmethadol

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [More information on Orlaam](#more-information-on-orlaam-1108)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Orlaam has been withdrawn at the request of the marketing authorisation holder.

## Product information

11/06/2002

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Orlaam Active substance levacetylmethadol International non-proprietary name (INN) or common name levacetylmethadol Therapeutic area (MeSH) Opioid-Related Disorders Anatomical therapeutic chemical (ATC) code N02AC

### Pharmacotherapeutic group

Analgesics

### Therapeutic indication

ORLAAM is indicated for the substitution maintenance treatment of opiate addiction in adults previously treated with methadone, as part of a comprehensive treatment plan including medical, social and psychological care.

ORLAAM should be administered under the supervision of physicians with experience in addiction treatment and whenever practicable, in centres specialising in the treatment of drug addiction.

ORLAAM is not intended for take home use.

## Authorisation details

EMA product number EMEA/H/C/000077 Marketing authorisation holder

Sipaco Internacional Lda.

Sipaco Internacional, Lda.

Marketing authorisation issued 01/07/1997

#### More information on Orlaam

Public statement on the recommendation to suspend the marketing authorisation for Orlaam (levacetylmethadol) in the European Union

Reference Number: EMEA/8776/01

English (EN) (50.44 KB - PDF)

**First published:** 19/04/2001

**Last updated:** 19/04/2001

[View](/en/documents/public-statement/public-statement-recommendation-suspend-marketing-authorisation-orlaam-levacetylmethadol-european-union_en.pdf)

**This page was last updated on** 30/06/2002

## Share this page

[Back to top](#main-content)